Herpes simplex virus 2 ICP0- mutant viruses are avirulent and immunogenic: Implications for a genital herpes vaccine

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  Halford, William P ^a   Püschel, Ringo ^a   Rakowski, Brandon ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERPES VACCINE; INFECTED CELL PROTEIN 0; INTERFERON; STAT1 PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; ALPHA INTERFERON; BETA INTERFERON; LIVE VACCINE; UBIQUITIN PROTEIN LIGASE; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION RESISTANCE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; VIRUS CHARACTERIZATION; VIRUS MUTANT; VIRUS REPLICATION; VIRUS VIRULENCE; ANIMAL; DISEASE TRANSMISSION; DRUG EFFECT; FEMALE; GENETICS; IMMUNOCOMPETENCE; IMMUNOLOGY; METABOLISM; MUTATION; PATHOGENICITY; SAFETY;

HERPES; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; MUS; SIMPLEXVIRUS;

ANIMALS; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; IMMUNOCOMPETENCE; INTERFERON-ALPHA; INTERFERON-BETA; MICE; MUTATION; SAFETY; STAT1 TRANSCRIPTION FACTOR; UBIQUITIN-PROTEIN LIGASES; VACCINES, ATTENUATED; VIRAL VACCINES;

EID: 77957882403     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012251     Document Type: Article

References (71)

1. Janier M, Scieux C, Meouchi R, Tournoux C, Porcher R, et al. (2006) Virological, serological and epidemiological study of 255 consecutive cases of genital herpes in a sexually transmitted disease clinic of Paris (France): a prospective study. Int J STD AIDS 17: 44-49.
2. Lowhagen GB, Tunback P, Andersson K, Bergstrom T, Johannisson G (2000) First episodes of genital herpes in a Swedish STD population: a study of epidemiology and transmission by the use of herpes simplex virus (HSV) typing and specific serology. Sex Transm Infect 76: 179-182.
3. Nieuwenhuis RF, van Doornum GJ, Mulder PG, Neumann HA, van der Meijden WI (2006) Importance of herpes simplex virus type-1 (HSV-1) in primary genital herpes. Acta Derm Venereol 86: 129-134.
4. Solomon L, Cannon MJ, Reyes M, Graber JM, Wetherall NT, et al. (2003) Epidemiology of recurrent genital herpes simplex virus types 1 and 2. Sex Transm Infect 79: 456-459.
5. Green J (2004) Psychosocial issues in genital herpes management. Herpes 11: 60-62.
6. Mark H, Gilbert L, Nanda J (2009) Psychosocial well-being and quality of life among women newly diagnosed with genital herpes. J Obstet Gynecol Neonatal Nurs 38: 320-326.
7. Newton DC, McCabe MP (2008) Sexually transmitted infections: impact on individuals and their relationships. J Health Psychol 13: 864-869.
8. CDC (2010) Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years-United States, 2005-2008. MMWR Morb Mortal Wkly Rep 59: 456-459.
9. Corey L, Adams HG, Brown ZA, Holmes KK (1983) Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med 98: 958-972.
10. Wald A, Corey L, Cone R, Hobson A, Davis G, et al. (1997) Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J Clin Invest 99: 1092-1097.
11. Gottlieb SL, Douglas JM, Jr., Foster M, Schmid DS, Newman DR, et al. (2004) Incidence of herpes simplex virus type 2 infection in 5 sexually transmitted disease (STD) clinics and the effect of HIV/STD risk-reduction counseling. J Infect Dis 190: 1059-1067.
12. Jonsson MK, Wahren B (2004) Sexually transmitted herpes simplex viruses. Scand J Infect Dis 36: 93-101.
13. Halford WP (2007) Towards an effective genital herpes vaccine: past lessons and future prospects. Future Virology 2: 1-6.
14. Jones CA, Cunningham AL (2004) Vaccination strategies to prevent genital herpes and neonatal herpes simplex virus (HSV) disease. Herpes 11: 12-17.
15. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, et al. (2002) Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 347: 1652-1661.
16. Bourne N, Bravo FJ, Francotte M, Bernstein DI, Myers MG, et al. (2003) Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. J Infect Dis 187: 542-549.
17. Dudek T, Knipe DM (2006) Replication-defective viruses as vaccines and vaccine vectors. Virology 344: 230-239.
18. Reszka NJ, Dudek T, Knipe DM (2010) Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein. Vaccine 28: 2754-2762.
19. Jacobs BL, Langland JO, Kibler KV, Denzler KL, White SD, et al. (2009) Vaccinia virus vaccines: past, present and future. Antiviral Res 84: 1-13.
20. Gershon AA (2001) Live-attenuated varicella vaccine. Infect Dis Clin North Am 15: 65-81, viii.
21. Wharton M, Cochi SL, Williams WW (1990) Measles, mumps, and rubella vaccines. Infect Dis Clin North Am 4: 47-73.
22. Sabin AB (1985) Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis 151: 420-436.
23. Thompson RL, Nakashizuka M, Stevens JG (1986) Vaccine potential of a live avirulent herpes simplex virus. Microb Pathog 1: 409-416.
24. Aurelian L, Kokuba H, Smith CC (1999) Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10). Vaccine 17: 1951-1963.
25. Prichard MN, Kaiwar R, Jackman WT, Quenelle DC, Collins DJ, et al. (2005) Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs. Vaccine 23: 5424-5431.
26. zur Hausen H (1979) Herpes simplex virus: benefit versus risk factors in immunization. Dev Biol Stand 43: 373-379.
27. Galea SA, Sweet A, Beninger P, Steinberg SP, Larussa PS, et al. (2008) The safety profile of varicella vaccine: a 10-year review. J Infect Dis 197 Suppl 2: S165-169.
28. Krause PR, Klinman DM (2000) Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children. Nat Med 6: 451-454.
29. Harpaz R, Ortega-Sanchez IR, Seward JF (2008) Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 57: 1-30; quiz CE32-34.
30. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, et al. (2005) A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352: 2271-2284.
31. Woolery WA (2008) Herpes zoster virus vaccine. Geriatrics 63: 6-9.
32. Halford WP, Schaffer PA (2001) ICP0 is required for efficient reactivation of herpes simplex virus type 1 from neuronal latency. J Virol 75: 3240-3249.
33. Liu M, Rakowski B, Gershburg E, Weisend CM, Lucas O, et al. (2010) ICP0 antagonizes ICP4-dependent silencing of the herpes simplex virus ICP0 gene. PLoS ONE 5: e8837.
34. Liu M, Schmidt EE, Halford WP (2010) ICP0 dismantles host cell microtubule networks in herpes simplex virus-infected cells. PLoS ONE 5: e10975.
35. Leib DA, Harrison TE, Laslo KM, Machalek MA, Moorman NJ, et al. (1999) Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo. J Exp Med 189: 663-672.
36. Mossman KL, Saffran HA, Smiley JR (2000) Herpes simplex virus ICP0 mutants are hypersensitive to interferon. J Virol 74: 2052-2056.
37. Halford WP, Weisend C, Grace J, Soboleski M, Carr DJ, et al. (2006) ICP0 antagonizes Stat 1-dependent repression of herpes simplex virus: implications for the regulation of viral latency. Virol J 3: 44.
38. Boutell C, Sadis S, Everett RD (2002) Herpes simplex virus type 1 immediateearly protein ICP0 and its isolated RING finger domain act as ubiquitin E3 ligases in vitro. J Virol 76: 841-850.
39. Boutell C, Everett R, Hilliard J, Schaffer P, Orr A, et al. (2008) Herpes simplex virus type 1 ICP0 phosphorylation mutants impair the E3 ubiquitin ligase activity of ICP0 in a cell type-dependent manner. J Virol 82: 10647-10656.
40. Davido DJ, von Zagorski WF, Lane WS, Schaffer PA (2005) Phosphorylation site mutations affect herpes simplex virus type 1 ICP0 function. J Virol 79: 1232-1243.
41. Chen J, Panagiotidis C, Silverstein S (1992) Multimerization of ICP0, a herpes simplex virus immediate-early protein. J Virol 66: 5598-5602.
42. Ciufo DM, Mullen MA, Hayward GS (1994) Identification of a dimerization domain in the C-terminal segment of the IE110 transactivator protein from herpes simplex virus. J Virol 68: 3267-3282.
43. Everett R, O'Hare P, O'Rourke D, Barlow P, Orr A (1995) Point mutations in the herpes simplex virus type 1 Vmw110 RING finger helix affect activation of gene expression, viral growth, and interaction with PML-containing nuclear structures. J Virol 69: 7339-7344.
44. Canning M, Boutell C, Parkinson J, Everett RD (2004) A RING finger ubiquitin ligase is protected from autocatalyzed ubiquitination and degradation by binding to ubiquitin-specific protease USP7. J Biol Chem 279: 38160-38168.
45. Harle P, Sainz B Jr, Carr DJ, Halford WP (2002) The immediate-early protein, ICP0, is essential for the resistance of herpes simplex virus to interferon-alpha/ beta. Virology 293: 295-304.
46. Halford WP, Schaffer PA (2000) Optimized viral dose and transient immunosuppression enable herpes simplex virus ICP0-null mutants To establish wild-type levels of latency in vivo. J Virol 74: 5957-5967.
47. Elion GB (1982) Mechanism of action and selectivity of acyclovir. Am J Med 73: 7-13.
48. van Ekdom LT, Versteeg J (1982) Preventive and curative effects of acyclovir on central nervous system infections in hamsters inoculated with herpes simplex virus. Am J Med 73: 161-164.
49. Halford WP, Gebhardt BM, Carr DJ (1997) Acyclovir blocks cytokine gene expression in trigeminal ganglia latently infected with herpes simplex virus type 1. Virology 238: 53-63.
50. Nicola AV, Willis SH, Naidoo NN, Eisenberg RJ, Cohen GH (1996) Structurefunction analysis of soluble forms of herpes simplex virus glycoprotein D. J Virol 70: 3815-3822.
51. Aaronson DS, Horvath CM (2002) A road map for those who know JAK-STAT. Science 296: 1653-1655.
52. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW (2002) Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285: 1-24.
53. de Veer MJ, Holko M, Frevel M, Walker E, Der S, et al. (2001) Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol 69: 912-920.
54. Pasieka TJ, Cilloniz C, Lu B, Teal TH, Proll SC, et al. (2009) Host responses to wild-type and attenuated herpes simplex virus infection in the absence of Stat1. J Virol 83: 2075-2087.
55. Singh M, Carlson JR, Briones M, Ugozzoli M, Kazzaz J, et al. (1998) A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2. Vaccine 16: 1822-1827.
56. Straus SE, Wald A, Kost RG, McKenzie R, Langenberg AG, et al. (1997) Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J Infect Dis 176: 1129-1134.
57. Stanberry LR (2004) Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 11 Suppl 3: 161A-169A.
58. Nagashunmugam T, Lubinski J, Wang L, Goldstein LT, Weeks BS, et al. (1998) In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor. J Virol 72: 5351-5359.
59. Hoshino Y, Pesnicak L, Dowdell KC, Lacayo J, Dudek T, et al. (2008) Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs. Vaccine 26: 4034-4040.
60. Bourne N, Milligan GN, Stanberry LR, Stegall R, Pyles RB (2005) Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected. J Infect Dis 192: 2117-2123.
61. Da Costa XJ, Jones CA, Knipe DM (1999) Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. Proc Natl Acad Sci U S A 96: 6994-6998.
62. Centifanto-Fitzgerald YM, Rayfield M, Tian PY, Kaufman HE (1985) Herpes simplex virus latency in the rabbit trigeminal ganglia: ganglionic superinfection. Proc Soc Exp Biol Med 179: 55-67.
63. Centifanto-Fitzgerald YM, Varnell ED, Kaufman HE (1982) Initial herpes simplex virus type 1 infection prevents ganglionic superinfection by other strains. Infect Immun 35: 1125-1132.
64. Klein RJ (1989) Reinfections and site-specific immunity in herpes simplex virus infections. Vaccine 7: 380-381.
65. Sengupta N, Booy R, Schmitt HJ, Peltola H, Van-Damme P, et al. (2008) Varicella vaccination in Europe: are we ready for a universal childhood programme? Eur J Pediatr 167: 47-55.
66. Watson RJ, Weis JH, Salstrom JS, Enquist LW (1982) Herpes simplex virus type-1 glycoprotein D gene: nucleotide sequence and expression in Escherichia coli. Science 218: 381-384.
67. Watson RJ, Enquist LW (1985) Genetically engineered herpes simplex virus vaccines. Prog Med Virol 31: 84-108.
68. Stanberry LR, Cunningham AL, Mindel A, Scott LL, Spruance SL, et al. (2000) Prospects for control of herpes simplex virus disease through immunization. Clin Infect Dis 30: 549-566.
69. Morrison LA, Da Costa XJ, Knipe DM (1998) Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge. Virology 243: 178-187.
70. Samaniego LA, Neiderhiser L, DeLuca NA (1998) Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J Virol 72: 3307-3320.
71. Halford WP, Halford KJ, Pierce AT (2005) Mathematical analysis demonstrates that interferons-beta and -gamma interact in a multiplicative manner to disrupt herpes simplex virus replication. J Theor Biol 235: 439-454.